ISAL 2019 | Improving the specificity of molecular MRD detection
Christopher Hourigan
• 24 Feb 2019
Measurable residual disease (MRD) is becoming increasingly important in the field of leukemia research, as emphasized here by Christopher Hourigan, DM, DPhil, FACP, FRCP, of the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD. Dr Hourigan discusses the challenges of specificity and false positives when using next-generation sequencing for MRD detection, and the methodologies that are working on overcoming these issues. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.
